These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26934062)

  • 1. Paliperidone for the treatment of schizoaffective disorder.
    Alphs L; Fu DJ; Turkoz I
    Expert Opin Pharmacother; 2016; 17(6):871-83. PubMed ID: 26934062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid onset of treatment effects on psychosis, depression, and mania in patients with acute exacerbation of schizoaffective disorder following treatment with oral extended-release paliperidone.
    Fu DJ; Turkoz I; Bossie CA; Patel H; Alphs L
    J Affect Disord; 2016 Mar; 193():381-90. PubMed ID: 26802315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder.
    Fu DJ; Turkoz I; Simonson RB; Walling D; Schooler N; Lindenmayer JP; Canuso C; Alphs L
    J Clin Psychopharmacol; 2016 Aug; 36(4):372-6. PubMed ID: 27322760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder.
    Fu DJ; Turkoz I; Simonson RB; Walling DP; Schooler NR; Lindenmayer JP; Canuso CM; Alphs L
    J Clin Psychiatry; 2015 Mar; 76(3):253-62. PubMed ID: 25562685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation.
    Mauri MC; Reggiori A; Paletta S; Di Pace C; Altamura AC
    Expert Opin Drug Saf; 2017 Mar; 16(3):365-379. PubMed ID: 28140680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review.
    Pacchiarotti I; Tiihonen J; Kotzalidis GD; Verdolini N; Murru A; Goikolea JM; Valentí M; Aedo A; Vieta E
    Eur Neuropsychopharmacol; 2019 Apr; 29(4):457-470. PubMed ID: 30770235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder.
    Joshi K; Lin J; Lingohr-Smith M; Fu DJ
    J Med Econ; 2015; 18(8):629-36. PubMed ID: 25800457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic drug evaluation of paliperidone in the treatment of schizoaffective disorder.
    Macaluso M; Oliver H; Sohail Z
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):871-879. PubMed ID: 28675307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recovery outcomes of schizophrenia patients treated with paliperidone palmitate in a community setting: patient and provider perspectives on recovery.
    Williams W; McKinney C; Martinez L; Benson C
    J Med Econ; 2016; 19(5):469-76. PubMed ID: 26671481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral and Palmitate Paliperidone Long-Acting Injectable Formulations' Use in Schizophrenia Spectrum Disorders: A Retrospective Cohort Study from the First Episode Psychosis Intervention Program (CRUPEP).
    Segarra R; Recio-Barbero M; Sáenz-Herrero M; Mentxaka O; Cabezas-Garduño J; Eguíluz JI; Callado LF
    Int J Neuropsychopharmacol; 2021 Sep; 24(9):694-702. PubMed ID: 34009370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Need for Bioequivalence Standards that Reflect the Clinical Importance of the Complex Pharmacokinetics of Paliperidone Palmitate Long-Acting Injectable Suspension.
    Procyshyn RM; Lamoure JW; Katzman MA; Skinner PL; Sherman SE
    J Pharm Pharm Sci; 2019; 22(1):548-566. PubMed ID: 31730504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paliperidone Long-Acting Plasma Level Monitoring and a New Method of Evaluation of Clinical Stability.
    Mauri MC; Paletta S; Di Pace C; Reggiori A; Rovera C; Fiorentini A; Altamura CA
    Pharmacopsychiatry; 2017 Jul; 50(4):145-151. PubMed ID: 28278537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate.
    Girardi P; Del Casale A; Rapinesi C; Kotzalidis GD; Splendori F; Verzura C; Trovini G; Sorice S; Carrus D; Mancinelli I; Comparelli A; De Filippis S; Francomano A; Ballerini A; Marcellusi A; Mennini FS; Ducci G; Sani G; Pompili M; Brugnoli R
    Hum Psychopharmacol; 2018 May; 33(3):e2658. PubMed ID: 29766576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers.
    Canuso CM; Schooler N; Carothers J; Turkoz I; Kosik-Gonzalez C; Bossie CA; Walling D; Lindenmayer JP
    J Clin Psychopharmacol; 2010 Oct; 30(5):487-95. PubMed ID: 20814330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder.
    Fu DJ; Turkoz I; Walling D; Lindenmayer JP; Schooler NR; Alphs L
    Schizophr Res; 2018 Feb; 192():185-193. PubMed ID: 28454922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The current data on the 3-month paliperidone palmitate formulation for the treatment of schizophrenia.
    Bioque M; Bernardo M
    Expert Opin Pharmacother; 2018 Oct; 19(14):1623-1629. PubMed ID: 30244607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.
    Morris MT; Tarpada SP
    Psychopharmacol Bull; 2017 May; 47(2):42-52. PubMed ID: 28626271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lithium carbonate as a treatment for paliperidone extended-release-induced leukopenia and neutropenia in a patient with schizoaffective disorder; a case report.
    Matsuura H; Kimoto S; Harada I; Naemura S; Yamamuro K; Kishimoto T
    BMC Psychiatry; 2016 May; 16():161. PubMed ID: 27229149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study.
    Ravenstijn P; Remmerie B; Savitz A; Samtani MN; Nuamah I; Chang CT; De Meulder M; Hough D; Gopal S
    J Clin Pharmacol; 2016 Mar; 56(3):330-9. PubMed ID: 26189570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A critical appraisal of paliperidone long-acting injection in the treatment of schizoaffective disorder.
    Chue P; Chue J
    Ther Clin Risk Manag; 2016; 12():109-16. PubMed ID: 26869795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.